MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Capricor Therapeutics Company Profile (OTCMKTS:CAPR)

Consensus Ratings for Capricor Therapeutics (OTCMKTS:CAPR) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.00

Analysts' Ratings History for Capricor Therapeutics (OTCMKTS:CAPR)
Show:
DateFirmActionRatingPrice TargetActions
6/15/2016Roth CapitalInitiated CoverageBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Capricor Therapeutics (OTCMKTS:CAPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/12/2016Q116($0.19)($0.26)$1.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2016Q415($0.19)($0.21)$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.26)($0.18)$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.26)($0.19)$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015($0.14)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/15/2015($0.14)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014($0.22)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Capricor Therapeutics (OTCMKTS:CAPR)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Capricor Therapeutics (OTCMKTS:CAPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Capricor Therapeutics (OTCMKTS:CAPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/16/2016Anthony BergmannVPBuy2,030$2.40$4,872.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Karen KrasneyEVPBuy4,060$2.40$9,744.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Leland GershellCFOBuy2,100$2.40$5,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Linda MarbanCEOBuy10,152$2.40$24,364.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Louis J GrasmickDirectorBuy91,369$2.40$219,285.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Sinai Medical Center CedarsMajor ShareholderBuy416,666$2.40$999,998.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Louis J. GrasmickDirectorBuy11,900$4.11$48,909.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2015Eduardo Marbanmajor shareholderBuy18,400$4.36$80,224.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Joshua A KazamDirectorBuy7,096$3.52$24,977.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Sinai Medical Center CedarsMajor ShareholderBuy851,546$3.52$2,997,441.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Capricor Therapeutics (OTCMKTS:CAPR)
DateHeadline
06/22/16 03:12 PMCapricor Therapeutics to Present at JMP Life Sciences Conference
06/16/16 03:03 PMCapricor Therapeutics (CAPR) Announces Statistically Significant Data on CAP-1002 in Adv. Heart Failure
06/16/16 03:03 PMCapricor Therapeutics Inc (CAPR) Stock Soars on Drug Data
06/16/16 09:39 AMCapricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial - [at noodls] - LOS ANGELES, June 16, 2016/PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, ...
06/16/16 07:31 AM8:31 am Capricor Therapeutics: CAP-1002 demonstrates durable efficacy signal over 12 months in patients with advanced heart failure -
06/15/16 06:03 AMCoverage initiated on Capricor Therapeutics by ROTH Capital -
06/09/16 03:04 PMGaps Down Stocks Highlight – URRE, CAPR, CATB, FLXN, ASC, PAY
06/07/16 03:04 PMCAPRICOR THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/06/16 04:31 PMCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/31/16 06:12 AMCapricor Therapeutics to Present at 2016 BIO International Convention - [at noodls] - LOS ANGELES, May 31, 2016/PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, ...
05/23/16 11:37 AMCapricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
02/26/16 12:47 PMCAPRICOR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K) - 2015 CAPRICOR THERAPEUTICS: Regulation FD Disclosure, Financial Statements and Exhib.. 2015 CAPRICOR THERAPEUTICS INC: Equities Driven By Market Influences - Research on C.. 2015 CAPRICOR THERAPEUTICS: Coalition Duchenne Presents Dr. Ron Victor of Cedars-Sin..
02/25/16 05:10 AMCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
02/23/16 08:00 AMCapricor Therapeutics Appoints Leland J. Gershell, M.D., Ph.D. as Chief Financial Officer - [PR Newswire] - LOS ANGELES, Feb. 23, 2016 /PRNewswire/ -- Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced the appointment of Leland J. Gershell, M.D., Ph.D. as Chief Financial Officer. Dr. Gershell brings to Capricor over 15 years of experience in the biotech sector, both within the industry and in finance as an equity research analyst and healthcare investor.
02/22/16 07:01 AMCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
02/22/16 07:00 AMCapricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial - [PR Newswire] - LOS ANGELES, Feb. 22, 2016 /PRNewswire/ -- Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced continuing enrollment of, and the treatment of the first patient with Duchenne Muscular Dystrophy (DMD)-related cardiomyopathy with CAP-1002 in the HOPE-Duchenne Phase I/II clinical trial (Halt cardiomyOPathy progrEssion in Duchenne). CAP-1002 is Capricor's allogeneic, cardiosphere-derived stem cell (CDC) therapy. The patient was treated at the Cincinnati Children's Hospital Medical Center under the direction of Dr. John Jefferies, the national principal investigator for the HOPE-Duchenne trial.
02/02/16 06:00 AMCapricor Therapeutics to Present at 18th Annual BIO CEO & Investor Conference - [PR Newswire] - LOS ANGELES, Feb. 2, 2016 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, ...
01/29/16 10:20 AMAlign Technology Tops Q4 Earnings, Revenues; Margins Drop -
01/28/16 01:22 PMThermo Fisher Tops Q4 Earnings, Affymetrix Buy in the Cards - Thermo Fisher presently carries a Zacks Rank #3 (Hold). Some better-ranked medical stocks are LeMaitre Vascular, Inc. LMAT, Capricor Therapeutics, Inc. CAPR and Vascular Solutions Inc. VASC. All the three stocks sport a Zacks Rank #1 (Strong Buy).
01/20/16 12:21 PMGNC Unveils 2015 Preliminary Outcome; Earnings Beat Likely - Zacks Rank Currently, GNC Holdings retains a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical sector are Abaxis, Inc. (ABAX - Analyst Report), Capricor Therapeutics, Inc. (CAPR - Snapshot Report) and LeMaitre Vascular, Inc. (LMAT ...
01/05/16 06:28 AMCapricor Therapeutics to Present at Biotech Showcase 2016 - [at noodls] - LOS ANGELES, Jan. 5, 2016/PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, ...
12/17/15 10:19 AMCapricor Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/10/15 04:05 PMCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
12/10/15 08:19 AMCapricor Therapeutics to Present at the 2015 JMP Securities DMD Forum - [at noodls] - LOS ANGELES, Dec. 10, 2015/PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, ...
12/08/15 12:18 PMCAPRICOR THERAPEUTICS, INC. Financials -
11/27/15 07:00 AMCapricor Therapeutics (CAPR) Looks Good: Stock Rises 7.5% -
11/24/15 06:11 AMCapricor Therapeutics to Present at the 2015 Piper Jaffray Healthcare Conference - [at noodls] - LOS ANGELES, Nov. 24, 2015/PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, ...
11/23/15 02:59 PMBioLife Solutions Customer Capricor Therapeutics Provides Update on Heart Failure Cell Therapy Safety Data at American Heart Association Scientific Sessions - [at noodls] - Clinical Grade CryoStor® Cryopreservation Media Used to Freeze and Administer Cells to Patients in DYNAMIC Clinical Trial BOTHELL, WA- November 23, 2015-BioLife Solutions, Inc. (NASDAQ: BLFS), the leading ...
11/13/15 03:32 PMCAPRICOR THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
About Capricor Therapeutics

Capricor Therapeutics logoCapricor Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease, with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development, which include CAP-1002, CAP-1001, CSps, Exosomes, Cenderitide (CD-NP) and CU-NP. The Company's technology is based in cardiospheres (CSps), which are multi-cell clusters of cardiac derived cells. The Company's product candidate, the cardiosphere-derived cells (CDC), is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: CAPR
  • CUSIP:
Key Metrics:
  • Previous Close: $4.38
  • 50 Day Moving Average: $3.58
  • 200 Day Moving Average: $3.01
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $75.04M
  • Current Quarter EPS Consensus Estimate: $-0.93 EPS
Additional Links:
Capricor Therapeutics (OTCMKTS:CAPR) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha